Worldwide Mononucleosis Diagnostic Industry to 2027 - Rising Health Awareness and Knowledge Among Patients is Driving Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Mononucleosis Diagnostic Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

The mononucleosis diagnostics market is expected to register a CAGR of nearly 4.8% during the forecast period, 2022-2027.

Companies Mentioned

• Abbott Laboratories
• Arlington Scientific Inc.
• Bio-Rad Laboratories Inc.
• Cardinal Health Inc.
• Danaher Corporation
• Immunostics Inc.
• Meridian Bioscience
• Quidel Corporation
• Sekisui Diagnostics
• Thermo Fischer Scientific Inc.
• Launch Diagnostics Limited
• Beckman Coulter Inc.

Key Market Trends

Monospot Test Segment by Test Type is Expected to Hold the Largest Market Share during the Forecast Period

By test type, the monospot test segment is expected to witness significant growth. A monospot test, also known as a heterophile antibody test, is a rapid test for the detection of infectious mononucleosis caused by the Epstein-Barr virus (EBV). This test is expected to hold the largest market share, owing to the benefits associated, such as non-interference with other tests, accurate results, rapid detection of antibodies, and cost-effectiveness.

Furthermore, an article titled "Mononucleosis" published in StatPearls, in August 2021, stated that Mononucleosis is diagnosed using the monospot (or heterophile antibody) test, which is nearly 100 percent specific for the disease. This test's sensitivity is closer to 85 percent. Such studies greatly increase the acceptance of monospot test type among the patient population, thereby, contributing to the segment's growth.

In addition, the major market players are focusing on the development of advanced products, which is expected to boost the market's growth. For instance, Launch Diagnostics offers a rapid latex test for the detection of heterophile antibodies specific to Infectious Mononucleosis (IM). Thus, the above-mentioned factors are expected to drive the growth of this segment over the forecast period.

Asia-Pacific Accounted for the Highest Growth Rate in the Global Market

The Asia-Pacific region holds the highest growth rate for the mononucleosis diagnostic market, and it is expected to show a similar trend over the forecast period, without significant changes. The rising adolescent population in the region susceptible to EBV infection is one of the major factors that is expected to drive the growth of the market over the forecast period.

For instance, according to an article published by Dr. Albert Saiz and Dr. Yolanda Blanco, in February 2022, stated that Mononucleosis is a disease that primarily affects adolescents and is caused by the Epstein-Barr virus. However, this virus is highly prevalent, with two maximum occurrence peaks in an individual's life, firstly around 3-4 years of age, and then secondly at 15-16 years of age. When an Epstein-Barr virus develops in childhood, the risk of developing Mononucleosis is quite low, but it is substantially higher in adolescence. This indicates that a large number of people are infected with the Epstein-Barr virus without being aware of the condition.

As per a 2019 update by the United Nations (UN), in 2019, Central and Southern Asia were home to the largest number of youth (361 million), followed by Eastern and South-Eastern Asia (307 million). The high youth population indicates the significant demand for mononucleosis diagnostic tests.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Health Awareness and Knowledge among Patients

4.2.2 Technological Advancements Leading to Faster Diagnosis

4.2.3 Rise in the Adolescent Population

4.3 Market Restraints

4.3.1 Limitations of Available Tests for the Diagnosis of Mononucleosis

4.4 Porter's Five Forces Analysis

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

5.1 By Type of Test

5.1.1 Monospot Test

5.1.2 Complete Blood Count Test

5.1.3 Epstein Barr Virus (EBV) Antibody Test

5.2 By End User

5.2.1 Hospitals

5.2.2 Laboratories

5.2.3 Other End Users

5.3 Geography

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Abbott Laboratories

6.1.2 Arlington Scientific Inc.

6.1.3 Bio-Rad Laboratories Inc.

6.1.4 Cardinal Health Inc.

6.1.5 Danaher Corporation

6.1.6 Immunostics Inc.

6.1.7 Meridian Bioscience

6.1.8 Quidel Corporation

6.1.9 Sekisui Diagnostics

6.1.10 Thermo Fischer Scientific Inc.

6.1.11 Launch Diagnostics Limited

6.1.12 Beckman Coulter Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/7v2l99